-DOCSTART- -X- O
The -X- _ O
highly -X- _ O
pathogenic -X- _ O
avian -X- _ O
influenza -X- _ O
( -X- _ O
HPAI -X- _ O
) -X- _ O
H5N1 -X- _ O
viruses -X- _ O
, -X- _ O
especially -X- _ O
the -X- _ O
laboratory-generated -X- _ O
H5N1 -X- _ O
mutants -X- _ O
, -X- _ O
have -X- _ O
demonstrated -X- _ O
the -X- _ O
potential -X- _ O
to -X- _ O
cross -X- _ O
the -X- _ O
species -X- _ O
barrier -X- _ O
and -X- _ O
infect -X- _ O
mammals -X- _ O
and -X- _ O
humans. -X- _ O
Consequently -X- _ O
, -X- _ O
the -X- _ O
design -X- _ O
of -X- _ O
an -X- _ O
effective -X- _ O
and -X- _ O
safe -X- _ O
anti-H5N1 -X- _ O
vaccine -X- _ O
is -X- _ O
essential. -X- _ O
We -X- _ O
previously -X- _ O
demonstrated -X- _ O
that -X- _ O
the -X- _ O
full-length -X- _ O
hemagglutinin -X- _ O
1 -X- _ O
( -X- _ O
HA1 -X- _ O
) -X- _ O
could -X- _ O
induce -X- _ O
significant -X- _ O
neutralizing -X- _ O
antibody -X- _ O
response -X- _ O
and -X- _ O
protection. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
intended -X- _ O
to -X- _ O
identify -X- _ O
the -X- _ O
critical -X- _ B-Intervention
neutralizing -X- _ I-Intervention
domain -X- _ I-Intervention
( -X- _ I-Intervention
CND -X- _ I-Intervention
) -X- _ I-Intervention
in -X- _ O
an -X- _ O
optimal -X- _ O
conformation -X- _ O
that -X- _ O
can -X- _ B-Outcome
elicit -X- _ I-Outcome
strong -X- _ I-Outcome
cross-neutralizing -X- _ I-Outcome
antibodies -X- _ I-Outcome
and -X- _ I-Outcome
protection -X- _ I-Outcome
against -X- _ I-Outcome
divergent -X- _ I-Outcome
H5N1 -X- _ I-Outcome
strains. -X- _ I-Outcome
We -X- _ O
thus -X- _ O
constructed -X- _ O
six -X- _ O
recombinant -X- _ O
proteins -X- _ O
covering -X- _ O
different -X- _ O
regions -X- _ O
of -X- _ O
HA1 -X- _ B-Patient
of -X- _ I-Patient
A -X- _ I-Patient
/ -X- _ I-Patient
Anhui -X- _ I-Patient
/ -X- _ I-Patient
1 -X- _ I-Patient
/ -X- _ I-Patient
2005 -X- _ I-Patient
( -X- _ I-Patient
H5N1 -X- _ I-Patient
) -X- _ I-Patient
, -X- _ O
each -X- _ O
of -X- _ O
which -X- _ O
was -X- _ O
fused -X- _ O
with -X- _ O
foldon -X- _ O
( -X- _ O
Fd -X- _ O
) -X- _ O
and -X- _ O
Fc -X- _ O
of -X- _ O
human -X- _ O
IgG. -X- _ O
We -X- _ O
found -X- _ O
that -X- _ O
the -X- _ O
critical -X- _ B-Outcome
fragment -X- _ I-Outcome
fused -X- _ I-Outcome
with -X- _ I-Outcome
Fd -X- _ I-Outcome
/ -X- _ I-Outcome
Fc -X- _ I-Outcome
( -X- _ I-Outcome
HA-13– -X- _ I-Outcome
263-Fdc -X- _ I-Outcome
, -X- _ I-Outcome
H5 -X- _ I-Outcome
numbering -X- _ I-Outcome
) -X- _ I-Outcome
that -X- _ I-Outcome
could -X- _ I-Outcome
elicit -X- _ I-Outcome
the -X- _ I-Outcome
strongest -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibody -X- _ I-Outcome
response -X- _ I-Outcome
is -X- _ I-Outcome
located -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
N-terminal -X- _ I-Outcome
region -X- _ I-Outcome
of -X- _ I-Outcome
HA1 -X- _ I-Outcome
( -X- _ I-Outcome
residues -X- _ I-Outcome
13–263 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ O
which -X- _ O
covers -X- _ O
the -X- _ O
receptor-binding -X- _ O
domain -X- _ O
( -X- _ O
RBD -X- _ O
, -X- _ O
residues -X- _ O
112–263 -X- _ O
) -X- _ O
. -X- _ O
We -X- _ O
then -X- _ O
constructed -X- _ O
three -X- _ O
additional -X- _ O
recombinants -X- _ O
fused -X- _ O
with -X- _ O
Fd -X- _ O
plus -X- _ O
His -X- _ O
tag -X- _ O
( -X- _ O
HA-13–263-Fd-His -X- _ O
) -X- _ O
, -X- _ O
Fc -X- _ O
only -X- _ O
( -X- _ O
HA-13–263-Fc -X- _ O
) -X- _ O
, -X- _ O
and -X- _ O
His -X- _ O
tag -X- _ O
only -X- _ O
( -X- _ O
HA-13–263-His -X- _ O
) -X- _ O
, -X- _ O
respectively. -X- _ O
We -X- _ O
found -X- _ O
that -X- _ O
the -X- _ O
HA-13–263-Fdc -X- _ B-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
formed -X- _ I-Outcome
an -X- _ I-Outcome
oligomeric -X- _ I-Outcome
conformation -X- _ I-Outcome
, -X- _ I-Outcome
induced -X- _ I-Outcome
the -X- _ I-Outcome
strongest -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibody -X- _ I-Outcome
response -X- _ I-Outcome
and -X- _ I-Outcome
cross-protection -X- _ I-Outcome
against -X- _ I-Outcome
challenges -X- _ I-Outcome
of -X- _ I-Outcome
two -X- _ I-Outcome
tested -X- _ I-Outcome
H5N1 -X- _ I-Outcome
virus -X- _ I-Outcome
strains -X- _ I-Outcome
covering -X- _ I-Outcome
clade -X- _ I-Outcome
1 -X- _ I-Outcome
: -X- _ I-Outcome
A -X- _ I-Outcome
/ -X- _ I-Outcome
VietNam -X- _ I-Outcome
/ -X- _ I-Outcome
1194 -X- _ I-Outcome
/ -X- _ I-Outcome
2004 -X- _ I-Outcome
( -X- _ I-Outcome
VN -X- _ I-Outcome
/ -X- _ I-Outcome
1194 -X- _ I-Outcome
) -X- _ I-Outcome
or -X- _ I-Outcome
clade -X- _ I-Outcome
2.3.4 -X- _ I-Outcome
: -X- _ I-Outcome
A -X- _ I-Outcome
/ -X- _ I-Outcome
Shenzhen -X- _ I-Outcome
/ -X- _ I-Outcome
406H -X- _ I-Outcome
/ -X- _ I-Outcome
06 -X- _ I-Outcome
( -X- _ I-Outcome
SZ -X- _ I-Outcome
/ -X- _ I-Outcome
406H -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
while -X- _ I-Outcome
HA-13–263-Fc -X- _ I-Outcome
dimer -X- _ I-Outcome
and -X- _ I-Outcome
HA-13–263-Fd-His -X- _ I-Outcome
trimer -X- _ I-Outcome
elicited -X- _ I-Outcome
higher -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibody -X- _ I-Outcome
response -X- _ I-Outcome
and -X- _ I-Outcome
protection -X- _ I-Outcome
than -X- _ I-Outcome
HA-13–263-His -X- _ I-Outcome
monomer. -X- _ I-Outcome
These -X- _ O
results -X- _ O
suggest -X- _ O
that -X- _ O
the -X- _ O
oligomeric -X- _ O
form -X- _ O
of -X- _ O
the -X- _ O
CND -X- _ B-Intervention
containing -X- _ I-Intervention
the -X- _ I-Intervention
RBD -X- _ I-Intervention
can -X- _ O
be -X- _ O
further -X- _ O
developed -X- _ O
as -X- _ O
an -X- _ O
effective -X- _ O
and -X- _ O
safe -X- _ O
vaccine -X- _ O
for -X- _ O
cross-protection -X- _ O
against -X- _ O
divergent -X- _ O
strains -X- _ O
of -X- _ O
H5N1 -X- _ B-Patient
viruses -X- _ I-Patient
. -X- _ O

